Pricing Log in Create free account

Atrium Therapeutics, Inc. (RNA) vs Entrada Therapeutics, Inc. (TRDA)

Atrium Therapeutics, Inc. and Entrada Therapeutics, Inc. are both Biotechnology companies. Atrium Therapeutics, Inc. and Entrada Therapeutics, Inc. are of similar size ($191.5M and $185.8M). Atrium Therapeutics, Inc. has the higher net margin (−203.7% vs −4,058.0%) and the higher return on invested capital (0.00% vs −2,009.0%). Across the 13 metrics below, Atrium Therapeutics, Inc. leads on 12 and Entrada Therapeutics, Inc. on 1.

Valuation

Metric RNA TRDA Biotechnology median
P/E n/m n/m 10.60
P/S 5.08 52.10 9.40
P/B 0.66 1.04 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 2.03 n/m 0.66
EV/Sales (4.33) 3.57 9.02
Earnings yield (40.03%) (78.53%) (32.88%)
Free cash flow yield (40.71%) (65.80%) (23.13%)

Profitability

Metric RNA TRDA Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (214.60%) (4,303.82%) 0.00%
Net margin (203.67%) (4,057.98%) 0.00%
Free cash flow margin (206.99%) (3,428.06%) 0.00%
Return on equity 0.00% (59.88%) (51.96%)
Return on assets (40.74%) (47.48%) (46.06%)
Return on invested capital 0.00% (2,008.96%) 0.00%

Growth

Metric RNA TRDA Biotechnology median
Revenue growth (TTM) — (93.54%) 6.76%
EPS growth (last fiscal year) — (306.55%) 29.88%
Revenue growth, 5-year CAGR 22.54% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RNA TRDA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.73 7.85 4.97
Net debt to EBITDA 9.08 1.88 1.01

Dividend

Metric RNA TRDA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric RNA TRDA Biotechnology median
Market cap 185.78m 191.45m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack